ORBA Wealth Advisors L.L.C. Reduces Stake in Pfizer Inc. (NYSE:PFE)

ORBA Wealth Advisors L.L.C. lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 8.3% in the fourth quarter, Holdings Channel reports. The fund owned 11,189 shares of the biopharmaceutical company’s stock after selling 1,014 shares during the quarter. ORBA Wealth Advisors L.L.C.’s holdings in Pfizer were worth $297,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Swedbank AB grew its holdings in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares during the period. Nisa Investment Advisors LLC grew its stake in Pfizer by 7.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,742,343 shares of the biopharmaceutical company’s stock valued at $50,423,000 after acquiring an additional 118,473 shares in the last quarter. Autumn Glory Partners LLC increased its holdings in Pfizer by 126.2% in the 3rd quarter. Autumn Glory Partners LLC now owns 30,250 shares of the biopharmaceutical company’s stock valued at $875,000 after acquiring an additional 16,875 shares during the last quarter. Orrstown Financial Services Inc. bought a new position in shares of Pfizer during the 3rd quarter valued at about $427,000. Finally, Pallas Capital Advisors LLC grew its position in shares of Pfizer by 54.8% during the third quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock valued at $736,000 after purchasing an additional 9,102 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.76 on Wednesday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm has a market capitalization of $151.62 billion, a P/E ratio of 18.98, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s fifty day moving average price is $26.33 and its 200 day moving average price is $27.37.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.43%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.